

**Company name: Minapharm pharmaceutical**

an audited Consolidated financial indicator for the financial year period ended on 30/06/2024.

Currency: EGP

(The form should include the company's comment on the results of the business with the most important factors that led to profit/loss)

**First, the Consolidated financial indicators**

(A) statement Consolidated of profit or loss for the year/period ended in 30/06/2024

	Current period	comparative financial statements	change%
Revenue/sales	2,067,415,579.00	2,043,368,953.00	1%
Total profit (loss) *	492,250,293.00	737,267,945.00	-33%
The ratio of total profit to revenue/sales	0.24	0.36	-34%
Net profit (loss) before tax from continuing activities	75,274,540.00-	217,962,763.00	-135%
Net profit (loss) before tax from non-continuing activities (if any)	-	-	0%
Net profit (loss) after tax	89,772,298.00-	147,374,749.00	-161%
Earnings / (losses) per share (EPS)	6.51-	13.17	-149%
Diluted share of profit / loss (if any)	-	-	0%

شركة مينافارم للأدوية والصناعات الكيماوية  
ط ٢ ش. البرديس من أسماء فهمى  
خلف الرقابة الإدارية - أرض الجولف

**Head Office: 2T Taksim Asmaa Fahmy Nasr City – Cairo – Egypt**  
**Factory: 10<sup>th</sup> of Ramadan City - Egypt**

Agree

We acknowledge that the above-mentioned statements are extracted from the Company's financial statements issued by the Board of Directors held on 28 / 08 / 2024 and have not yet issued the auditor's report and we undertake to promptly disclose to FRA and EGX if any change in these statements as soon as it occurs until the submission of the signed financial statements which we undertake to send immediately after Issue the auditor/auditor's report before the beginning of the trading session of the following day according to the date recorded in the auditor's report, which we expect to be a " clean" report .


(if amended, please state the reasons given in the annex (No. 2)).

Investor relations officer



Date 28 / 08 / 2024

Chairman



The company's stamp.

شركة مينافارم للأدوية والصناعات الكيماوية  
ط ٢ ش. البرديس من أسماء فهمي  
خلف الرقابة الإدارية - أرض الجولف

Head Office: 2T Taksim Asmaa Fahmy Nasr City – Cairo – Egypt  
Factory: 10<sup>th</sup> of Ramadan City - Egypt

Tel.: ++(2015) 413015 - 413015 Fax. : ++2015 413009 Internet [www.minapharm.com](http://www.minapharm.com)

**Caution:** This attachment should be prepared on the official publications of the company and sent as an annex to the summary of the decisions of the Board of Directors before the first trading session following the date of the meeting.

Annex (1):

Material events that have occurred since the date of the financial results till now and should be disclosed:

Annex (2)

Reasons to expect the auditor not to issue a clean report:

شركة مينا فارم للأدوية والصناعات الكيماوية  
٢ ط ش. البرديس من أسماء فهمى  
خلف الرقابة الإدارية - أرض الجولف